Katrin L. Dubischar
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.
Journal: Nature medicine
Published: July 07, 2025
Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.
Journal: Emerging microbes & infections
Published: February 25, 2025
Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine†.
Journal: Journal of travel medicine
Published: July 31, 2024
From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.
Journal: Journal of travel medicine
Published: June 30, 2024
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.
Journal: The Lancet. Infectious diseases
Published: May 16, 2024
Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine.
Journal: Journal of travel medicine
Published: May 01, 2024
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: April 09, 2024
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study.
Journal: The Lancet. Infectious diseases
Published: March 19, 2024
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.
Journal: Journal of travel medicine
Published: October 12, 2023
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies.
Journal: The Lancet. Infectious diseases
Published: September 20, 2023
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Journal: The Journal of infection
Published: May 04, 2023
Last Updated: 09/26/2026